Sino Biopharmaceutical Limited (HKSE: 1177.HK) AI-Powered Stock Analysis
See how Sino Biopharmaceutical Limited scores across key metrics like financial growth, valuation, and market position on the HKSE, using AI-driven evaluation.
1177.HK●HKSE
HealthcareMedical - Pharmaceuticals
HK$5.41
HK$0.23(4.08%)
Hong Kong Market is Open · 12:02
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continuously improving this model to increase accuracy and performance.Read our Full DisclaimerSino Biopharmaceutical Limited (HKSE: 1177.HK) Stock Overall Grade
Sino Biopharmaceutical Limited's grade for its HKSE listing, based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Sino Biopharmaceutical Limited's overall HKSE stock rating.
Forecast
C+Score
59/100Financial Growth
B+Score
75/100Fundamental Growth
B+Score
77/100Key Ratios
B+Score
74/100Sector Comparison
B+Score
75/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
98/100Analyst Consensus
C+Score
50/100Sino Biopharmaceutical Limited (HKSE: 1177.HK) AI-Powered Stock Analysis
On the HKSE, 1177.HK demonstrates Good performance with an overall Forecast Score of 59/100 (C+), reflecting weak confidence in its potential. Financial Growth (75/100, B+) and Fundamental Growth (77/100, B+) highlight its stability, while Key Ratios (74/100, B+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (98/100, A+), the HKSE-listed stock shows competitive strength. Analyst Consensus (50/100, C+) suggests High divergence in outlook.(HKSE: 1177.HK) Component Analysis Explained
Understand the key factors behind each Sino Biopharmaceutical Limited (HKSE: 1177.HK) stock grade, including financials, comparisons, and forecasts.